Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight decrease in revenue but an increase in net profit compared to the previous year. The financial report highlights a net increase in cash and cash equivalents, along with a rise in total assets and owner’s equity, indicating a strong financial position despite the revenue dip. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. It holds a significant equity interest in Jiangzhong Pharmaceutical, a company listed on the Shanghai Stock Exchange, which is a key player in the Chinese pharmaceutical market.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.5B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue